Ontamalimab clinical trials
Also written PF-00547659 and SHP647.
How each study uses ontamalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses ontamalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4TerminatedPhase 1TakedaNCT07052682Written as Ontamalimab
- A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)CompletedPhase 3ShireNCT03283085Written as 25 mg Ontamalimab
- Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)TerminatedPhase 3ShireNCT03627091Written as Ontamalimab
- An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative ColitisCompletedPhase 3ShireNCT03290781Written as Ontamalimab
- Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedPhase 3ShireNCT03259334Written as Ontamalimab
- A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative ColitisCompletedPhase 2ShireNCT01620255Written as PF-00547659 SC Injection
- A Study To Monitor Long-Term Treatment With PF-00547659CompletedPhase 2ShireNCT01298492Written as PF-00547659
- Long-Term Safety Of PF-00547659 In Ulcerative ColitisCompletedPhase 2ShireNCT01771809Written as 75mg SHP647 (PF-00547659)
- Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's DiseaseCompletedPhase 2ShireNCT01276509Written as PF-00547659 SC injection
- Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)TerminatedPhase 3ShireNCT03566823Written as Ontamalimab
- Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)TerminatedPhase 3ShireNCT03559517Written as Ontamalimab
- Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedPhase 3ShireNCT03259308Written as Ontamalimab
Codes
What other systems call ontamalimab · ClinicalTrials.gg INT000217
- MeSH (NLM) C000597368ontamalimabOne source NLM
- UNII (FDA) 6LGI7RV4PBONTAMALIMABConfirmed FDA, NLM
- NCI Thesaurus C166947OntamalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000597368 | ontamalimab | One source NLM |
| UNII (FDA) | 6LGI7RV4PB | ONTAMALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C166947 | Ontamalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.